Skip to content

Assessment of Peripheral Veins Doppler Ultrasound for Diagnosis of Acute Right Heart Failure in Suspicion or Follow-up of Pulmonary Hypertension

Assessment of Peripheral Veins Doppler Ultrasound for Diagnosis of Acute Right Heart Failure in Suspicion or Follow-up of Pulmonary Hypertension

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04792879
Acronym
CODOVEIN
Enrollment
103
Registered
2021-03-11
Start date
2021-06-14
Completion date
2022-11-21
Last updated
2022-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Right Heart Failure, Peripheral Veins Doppler Ultrasound, Pulmonary Hypertension

Brief summary

Occurrence of acute right heart failure (ARHF) remains common during pulmonary hypertension (PH). Right atrial pressure (RAP) invasive measurement is the gold standard to diagnose ARHF in order to improve diuretic treatment management. Existence of indirect signs of ARHF on venous Doppler ultrasound waveform has long been described, but correlation with RAP has not been properly established yet. It is the aim of our study in order to obtain an additional tool to manage ARHF.

Interventions

DIAGNOSTIC_TESTPeripheral veins Doppler ultrasound

Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.

Sponsors

Poitiers University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (age ≥ 18 years old) * Patient referred to the cardiology department for a right heart catheterization with measurement of RAP, regardless of the indication. * Free subject, without guardianship or curatorship or subordination * People affiliated to or beneficiary of a social security schemes * Informed consent signed by the patient after clear and fair information about the study.

Exclusion criteria

* Minor patient (age \< 18 years) * Refusal to participate in the study * Patient with hemodynamic instability, unable to tolerate a delay in treatment caused by the ultrasound examination. * Patient requiring diuretic treatment within the next 4 hours * Patient with a life expectancy of less than 24 hours. * History of proximal deep venous thrombosis involving the inferior vena cava and/or common iliac veins and/or femoral veins. * History of extrinsic venous compression on the inferior vena cava and/or common iliac veins and/or femoral veins. * Persons who do not benefit from a Social Security scheme or who do not benefit from it through a third party. * Persons benefiting from reinforced protection, namely minors, pregnant and nursing women, persons deprived of liberty by a judicial or administrative decision, persons staying in health or social institutions, adults under legal protection and finally patients in emergency situations.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity, specificity, positive and negative likelihood ratios of venous stasis indexInclusion day within 4 hours before the right heart catheterizationSensitivity, specificity, positive and negative likelihood ratios of venous stasis index\*, measured by Pulsed Doppler on common femoral veins, as a diagnostic criterion for ARHF (defined by RAP ≥10 mm Hg). \* Defined as duration of non-anterograde venous flow during 3 seconds/ 3 seconds

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026